Andrew Zappia, a partner in Troutman Pepper Locke's Health Care + Life Sciences Intellectual Property group

24 November 2025FeaturesAmericasAndrew Zappia

Still Unsettling: The uncertain landscape for discretionary denial

The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Masimo convinces judge that Apple took secrets—but it’s not enough

19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.

Americas

J&J unit targets former employee over alleged mass data theft

17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.

Americas

Mylan withdraws defence claims against Novo in Wegovy dispute

13 March 2026 A proposed judgment by the rivals would extend the period in which Mylan is barred from obtaining regulatory approval for its generic of the weight-loss injectable.

More features

WIPR debuts Global In-House Elite 2026

mRNA litigation: Who’s winning, who’s filing, and what’s next

Dechert boosts litigation bench with partner duo

EPO reports record patent filings, but pharma and biotech lag

Part II: The race to replace semaglutide heats up

Masimo convinces judge that Apple took secrets—but it’s not enough

Sandoz strikes fresh biosimilar deal with South Korean biotech

US firm boosts patent bench with Desmarais hire

Still Unsettling: The uncertain landscape for discretionary denial

More on this story

Editor's picks

Editor's picks

More features